IP
CLDX icon

Intellectus Partners’s Celldex Therapeutics CLDX Stock Holding History

Intellectus Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-266
Closed -$1K – 216
2019
Q1 		$1K Buy
+266
New +$1.4K ﹤0.01% 421
2018
Q4 		– Sell
-267
Closed -$2K – 296
2018
Q3 		$2K Hold
267
– – ﹤0.01% 554
2018
Q2 		$2K Hold
267
– – ﹤0.01% 562
2018
Q1 		$9K Hold
267
– – ﹤0.01% 483
2017
Q4 		$11K Hold
267
– – ﹤0.01% 468
2017
Q3 		$11K Hold
267
– – ﹤0.01% 605
2017
Q2 		$10K Hold
267
– – ﹤0.01% 592
2017
Q1 		$14K Hold
267
– – 0.01% 499
2016
Q4 		$14K Buy
+267
New +$15.2K 0.01% 486

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Intellectus Partners's CLDX Position: Q2 2019 in Review

Intellectus Partners sold out of Celldex Therapeutics (CLDX) in Q2 2019, closing a stake of 266 shares — an estimated $1K sold.

Intellectus Partners first reported a position in CLDX in Q4 2016 and held it in 9 quarters. The position peaked at $14K in Q1 2017. 51 funds tracked by Wall St. Rank hold CLDX as of Q2 2019.

  • Intellectus Partners reported no remaining Celldex Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Intellectus Partners sold 266 Celldex Therapeutics shares in Q2 2019, an estimated $1K.
  • Intellectus Partners first reported a position in Celldex Therapeutics in Q4 2016 and held it in 9 quarters.
  • Intellectus Partners's Celldex Therapeutics position peaked at $14K in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2019.

Based on Intellectus Partners's 13F filing for Q2 2019, filed 8 Aug 2019.